PLoS Biology (Mar 2017)

The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease.

  • Rita Machado de Oliveira,
  • Hugo Vicente Miranda,
  • Laetitia Francelle,
  • Raquel Pinho,
  • Éva M Szegö,
  • Renato Martinho,
  • Francesca Munari,
  • Diana F Lázaro,
  • Sébastien Moniot,
  • Patrícia Guerreiro,
  • Luis Fonseca-Ornelas,
  • Zrinka Marijanovic,
  • Pedro Antas,
  • Ellen Gerhardt,
  • Francisco Javier Enguita,
  • Bruno Fauvet,
  • Deborah Penque,
  • Teresa Faria Pais,
  • Qiang Tong,
  • Stefan Becker,
  • Sebastian Kügler,
  • Hilal Ahmed Lashuel,
  • Clemens Steegborn,
  • Markus Zweckstetter,
  • Tiago Fleming Outeiro

DOI
https://doi.org/10.1371/journal.pbio.2000374
Journal volume & issue
Vol. 15, no. 3
p. e2000374

Abstract

Read online

Sirtuin genes have been associated with aging and are known to affect multiple cellular pathways. Sirtuin 2 was previously shown to modulate proteotoxicity associated with age-associated neurodegenerative disorders such as Alzheimer and Parkinson disease (PD). However, the precise molecular mechanisms involved remain unclear. Here, we provide mechanistic insight into the interplay between sirtuin 2 and α-synuclein, the major component of the pathognomonic protein inclusions in PD and other synucleinopathies. We found that α-synuclein is acetylated on lysines 6 and 10 and that these residues are deacetylated by sirtuin 2. Genetic manipulation of sirtuin 2 levels in vitro and in vivo modulates the levels of α-synuclein acetylation, its aggregation, and autophagy. Strikingly, mutants blocking acetylation exacerbate α-synuclein toxicity in vivo, in the substantia nigra of rats. Our study identifies α-synuclein acetylation as a key regulatory mechanism governing α-synuclein aggregation and toxicity, demonstrating the potential therapeutic value of sirtuin 2 inhibition in synucleinopathies.